| Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML? | |
| | |
MedLine Citation:
|
PMID: 18342809 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Gene expression profiling, the simultaneous measurement of the global patterns of gene expression in cells using microarray technologies, has held promise to improve diagnosis, risk classification, and outcome prediction in acute leukemias as well as in other human cancers. But how much has gene expression profiling impacted or improved current diagnosis and risk classification schemes and therapeutic targeting in acute myeloid leukemia (AML)? To date, gene expression profiling of AML has largely confirmed the presence of well-established recurring cytogenetic abnormalities, such as translocations, deletions, point mutations, or normal karyotypes, and has led to the identification of sets of genes reflective of these abnormalities. The use of expression profiling and statistical modeling to develop molecular classifiers that improve outcome prediction beyond traditional prognostic variables or the targeting of patients to specific therapies or transplantation has been less successful. Similarly, expression profiling has not led to the identification of many novel therapeutic targets in AML. Using advanced statistical modeling techniques, our group has focused on expression profiling in adult AML patients with poor risk features in order to identify novel cluster groups and potential targets for therapy in this highly resistant form of disease. To further advance the application of gene expression profiling and other comprehensive genomic and phosphoproteomic techniques to the study of AML, it would be ideal for the NCI Cooperative Groups to register all patients to common or intergroup collaborative clinical trials or registration studies in order to develop large, well-characterized cohorts of uniformly treated patients for future research studies. |
| | |
Authors:
|
Cheryl L Willman |
Related Documents
:
|
1886719 - Two site-specific deletions and t(1;14) translocation restricted to human t-cell acute ... 12543779 - Brd4-nut fusion oncogene: a novel mechanism in aggressive carcinoma. 15522959 - Hoxb6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor in v... 19380029 - Nup98-nsd3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p1... 16804919 - Transforming potential of the t-cell acute lymphoblastic leukemia-associated homeobox g... 16638849 - Identification of a set of seven genes for the monitoring of minimal residual disease i... 9675819 - Functional analysis of the saccharomyces cerevisiae ubc11 gene. 10491319 - Cloning and characterization of the murine histone deacetylase (hdac3). 16029449 - Hypermethylation of the suppressor of cytokine signalling-1 (socs-1) in myelodysplastic... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Best practice & research. Clinical haematology Volume: 21 ISSN: 1521-6926 ISO Abbreviation: Best Pract Res Clin Haematol Publication Date: 2008 Mar |
Date Detail:
|
Created Date: 2008-03-17 Completed Date: 2008-06-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101120659 Medline TA: Best Pract Res Clin Haematol Country: England |
Other Details:
|
Languages: eng Pagination: 21-8 Citation Subset: IM |
Affiliation:
|
University of New Mexico Cancer Center, Cancer Research Facility, 2325 Camino de Salud NE, Room G03, Albuquerque, NM 87131, USA. cwillman@salud.unm.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Cohort Studies Cytogenetic Analysis Female Gene Expression Profiling* Humans Leukemia, Myeloid, Acute* / classification, drug therapy, genetics, pathology Male Middle Aged Mutation Oligonucleotide Array Sequence Analysis Prognosis Registries* Survival Analysis Treatment Outcome |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Can FLT3 inhibitors overcome resistance in AML?
Next Document: New approaches in acute myeloid leukemia.